TODD STRATEGY GROUP lobbying for NOVARTIS, INC.

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 5

PAUL EDATTEL

Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
DANIEL M TODD

Previously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
NICHOLAS UEHLECKE

Previously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
ERIC BERGREN

Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
NICOLAS MAGALLANES

Previously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Trade (domestic/foreign)

Outbound investment issues.

Health Issues

Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight. Accelerated Approval. Breast Cancer Research. Supply Chain Integrity and Traceability. PBM Reform. Coverage of Accelerated Approval Products. Drug Benefit Design. Orphan Drug Issues. S. 1682/H.R.946: ORPHAN Cures Act. Reimbursement and Coverage of Innovative Products. Lower Costs, More Transparency Act. Lower Costs, More Cures Act. Patient Cost-Sharing. Step Therapy. Value-based Contracting and Communications. User fee policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Drug importation policy issues. Competition policy issues. Drug shortages policy issues. IRA price negotiation expansion policy issues. Rare Pediatric Disease Priority Review Voucher program policies. SUSTAIN RFI/discussion draft. Most Favored Nation (MFN) policy. Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Utilization management policies.

Medicare/Medicaid

Medicare Part B. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues. H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025. Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. Medicaid rebate policy issues.

Bills named in this filing 3

S. 1682
Alex Gate Safety Act of 2025
H.R. 946
ORPHAN Cures Act
H.R. 1672
Maintaining Investments in New Innovation Act